Skip to main
ENLV
ENLV logo

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics Ltd demonstrates a positive outlook due to its robust cash management strategy with an existing at-the-market (ATM) facility, which enhances liquidity for the development of Allocetra while maintaining operational momentum. The company has reported clinically meaningful and statistically significant results in its Phase IIa trial, particularly among patients aged 60 and older with idiopathic age-related osteoarthritis, indicating strong potential demand in a significant market segment. Additionally, recent corporate developments, including the filing of a patent application for Allocetra in osteoarthritis, bolster the company's intellectual property position and support future growth opportunities in addressing unmet medical needs.

Bears say

Enlivex Therapeutics has recently pivoted its strategy, necessitating additional time to assess the broader implications, which contributes to a cautious outlook. The disconnect between clinical advancements and market response has led management to explore unconventional capital access methods and redefine engagement through a digital asset strategy. Furthermore, while the KOA program may offer de-risking opportunities contingent on consistent Phase IIa data, uncertainties surrounding the strategy pivot and investor sentiment could negatively impact the company's stock performance.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.